GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2011

Theraclone Inks mAb Discovery Deal with Pfizer

Theraclone Inks mAb Discovery Deal with Pfizer

Agreement covers two targets in infectious diseases and two targets in cancer.[]

  • Theraclone Sciences will work with Pfizer to develop mAbs against up to two infectious disease targets and up to two cancer targets. Theraclone is eligible to receive royalties on sales of any developed products and up to $632 million in research funding and milestone fees related to discovery, development, regulatory, and commercialization goals.

    Pfizer gains an exclusive, worldwide license to any therapeutic antibodies discovered under the collaboration. The company will be responsible for preclinical and clinical development of all candidates.

    Theraclone’s I-STAR™ technology is used to screen and identify antibodies to pathogenic agents and endogenous therapeutic targets. The technology allows interrogation of B cells where the immunological history of protective responses is archived.

    “The I-STAR platform has been designed to discover broadly reactive, potent antibodies with high specificity for valuable targets,” comments Steven Gillis, Ph.D., interim CEO of Theraclone and managing director of ARCH Venture Partners. “This collaboration with Pfizer, and the recent published success of I-STAR to identify unique antibodies against novel targets in HIV and influenza, increase confidence in Theraclone’s approach to search the human immune repertoire to isolate rare and powerful human antibodies that may be of use in the treatment of multiple diseases.”

    “Antibodies represent a very exciting class of biotherapeutics for Pfizer to combat infectious disease and are a proven approach to cancer treatment,” commented Jose-Carlos Gutiérrez-Ramos, Pfizer’s svp of worldwide biotherapeutics R&D. “Theraclone’s platform technology represents an important advancement in fully human therapeutic antibody discovery, which we believe has the potential to deliver a new generation of improved therapeutic antibodies more efficiently.”

    Theraclone’s antibodies in preclinical development include mAbs against HIV, influenza, and inflammation. The International AIDS Vaccine Initiative has tapped into Theraclone, and Zenyaku Kogyo has a Japanese license to Theraclone’s influenza program.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »